RECOMMENDATIONS FOR THE MEDICAL MANAGEMENT OF OSTEOARTHRITIS OF THE HIP AND KNEE

Submitted for publication January 29, 2000; accepted in revised form May 12, 2000.

Address reprint requests to American College of Rheumatology, 1800 Century Place, Suite 250, Atlanta, GA 30345.

Members of the Subcommittee on Osteoarthritis Guidelines are as follows. Roy D. Altman, MD: Department of Veterans Affairs Medical Center, and University of Miami School of Medicine, Miami, Florida; Marc C. Hochberg, MD, MPH: University of Maryland School of Medicine, Baltimore; Roland W. Moskowitz, MD: Case Western Reserve University School of Medicine, Cleveland, Ohio; Thomas J. Schnitzer, MD, PhD: Northwestern University Medical School, Chicago, Illinois.

Members of the Subcommittee have relationships with the following pharmaceutical or biotechnology companies. Roy D. Altman, MD: Abbott, Aventis Pharmaceutical Co., Boehringer-Ingelheim, Eutovita, Fidia Co., Johnson & Johnson, Ortho-McNeil, Merck Sharp and Dohme, Novartis, Pierre Farber, Procter and Gamble, Sanofi, Searle, United Therapeutics, Whitehall Robbins, Negma, and NeuColl Corp. Marc C. Hochberg, MD, MPH: Merck & Co., Aventis Pharmaceutical Co., NEGMA Laboratories, Procter and Gamble, Roche, Wyeth-Ayerst, Johnson & Johnson, Eli Lilly, and Schering Plough. Roland W. Moskowitz, MD: Searle (Pharmacia), Sanofi-Synthelab, Fidia Co., and NeuColl Corp. Thomas J. Schnitzer, MD, PhD: Abbott, Boehringer-Ingelheim, Johnson & Johnson, McNeil Consumer, Merck & Co., Novartis, Ortho-McNeil, Parke-Davis, Searle, Wyeth-Ayerst, and SmithKline Beecham.

The American College of Rheumatology is an independent professional, medical, and scientific society which does not guarantee, warrant, or endorse any commercial product or service.